Abstract
For medicine today, the ultimate goal of most research-based pharmaceutical and allied health care organisations around the world is to discover, develop and procure necessary regulatory approvals for marketing new drugs for treatment or prevention of diseases in humans and animals. Drug discovery and development involves a complex process from early discovery of a chemical entity to demonstration of its safety and effectiveness for specific therapeutic indication(s). Introduction of new drugs either could be in the form of new chemical entities, or from regulatory perspectives a drug might be considered ‘new’ because of changes in its composition, route of administration, recommended dosage or dosage form. This chapter will deal primarily with pharmaceutical considerations for development of new chemical entities only, which usually require the greatest amount of investigation for safety and clinical evaluation to demonstrate their effectiveness. A comprehensive discussion of all pharmaceutical considerations in the design and development of all dosage forms or drug delivery systems for all routes of administration is beyond the scope of this chapter. An overview of critical pharmaceutical considerations for dosage forms generally developed for preclinical and early human testing will be covered.
Preview
Unable to display preview. Download preview PDF.
References
Amidon, G. L., Sinko, P. J. and Fleisher, D. (1988). Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm. Res., 5, 651–4
Anderson, B. D., Conradi, R. A. and Knuth, K. E. (1985a). Strategies in the design of solution-stable, water-soluble prodrugs. I. A physical-organic approach to promoiety selection for 21-esters of corticosteroids. J. Pharm. Sci., 74, 365–74
Anderson, B. D., Conradi, R. A., Knuth, K. E. and Nail, S. L. (1985b). Strategies in the design of solution-stable, water-soluble prodrugs. II. Properties of micellar prodrugs of methylprednisolone. J. Pharm. Sci., 74, 375–81
Anderson, B. D., Conradi, R. A., Spillman, C. H. and Forbes, A. D. (1985c). Strategies in the design of solution-stable, water-soluble prodrugs. III. Influence of the promoiety on the bioconversion of 21-esters of corticosteroids. J. Pharm. Sci., 74, 382–7
Dighe, S. (1988). FDAs new policy on supplemental ANDAs for ‘BP’ rated products, requires in vivo bioequivalency data, may upgrade ratings to ‘AB’. FDC Reports, 50(39), 8
Florence, A. T. (1981). In Yalkowsky, S. H. (Ed.), Techniques of Solubilization of Drugs, Marcel Dekker, New York, pp. 15–89
Morris, M. E. (1978). Compatibility and stability of diazepam injection following dilution with intravenous fluids. Am J. Hosp. Pharm., 35, 669–72
Reed, K. W. and Yalkowsky, S. H. (1985). Lysis of human red blood cells in the presence of various cosolvents. J. Parenteral Sci. Tech., 39, 64–9
Schroeder, H. G. and DeLuca, P. P. (1974). A study on the in vitro precipitation of poorly soluble drugs from nonaqueous vehicles in human plasma. Bull. Parenteral Drug Ass., 28, 1–14
Sinkula, A. A., Morozowich, W. and Rowe, E. L. (1973). Chemical modification of clindamycin: synthesis and evaluation of selected esters. J. Pharm. Sci., 62, 1106
Wang, Y. J. and Korwal, R. R. (1980). Review of excipients and pHs for parenteral products used in the United States. J. Parenteral Drug Ass., 34, 452–62
Yalkowsky, S. H. and Valvani, S. C. (1977). Precipitation of solubilized drugs due to injection or dilution. Drug Intell. Clin. Pharm., 11, 417–19
Yalkowsky, S. H., Valvani, S. C. and Johnson B. W. (1983). In vitro method for detecting precipitation of parenteral formulations after injection. J. Pharm. Sci., 72, 1014–17
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Copyright information
© 1990 The editors and contributors
About this chapter
Cite this chapter
Valvani, S.C. (1990). The Pharmaceutical Background. In: O’Grady, J., Linet, O.I. (eds) Early Phase Drug Evaluation in Man. Palgrave, London. https://doi.org/10.1007/978-1-349-10705-6_1
Download citation
DOI: https://doi.org/10.1007/978-1-349-10705-6_1
Publisher Name: Palgrave, London
Print ISBN: 978-1-349-10707-0
Online ISBN: 978-1-349-10705-6
eBook Packages: EngineeringEngineering (R0)